血友病创新疗法芬妥司兰钠注射液获批,一年最少6针皮下注射

新京报
Dec 11, 2025

新京报讯(记者王卡拉)12月10日,赛诺菲宣布,旗下全球首个且唯一血友病siRNA(小干扰RNA)创新非因子疗法芬妥司兰钠注射液(商品名为赛菲因)已获得国家药监局(NMPA)批准上市,适用于存在或不存在凝血因子Ⅷ抑制物的重型A型血友病、存在或不存在凝血因子Ⅸ抑制物的重型B型血友病12岁及以上儿童和成人患者的常规预防治疗,以防止出血或降低出血发作的频率。血友病是我国首批被纳入罕见病目录的疾病之一,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10